<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11796">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544882</url>
  </required_header>
  <id_info>
    <org_study_id>DR-DSG-302</org_study_id>
    <nct_id>NCT00544882</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Double-Blind Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With the Oral Contraceptive Regimen DR-1021</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products, R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center study to evaluate hormone levels with the oral contraceptive regimen
      DR-1021.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Female volunteers, aged 18-35 years old who met all Inclusion and no Exclusion Criteria,
      were enrolled in this study. All participants were current users of a standard 21/7 oral
      contraceptive regimen (21 days of combination progestin/estrogen followed by 7 days placebo)
      and had completed at least one 28-day cycle prior to beginning the Cycle 1 baseline cycle.
      After completing screening, all enrolled participants continued to receive the same regimen
      of 150 μg DSG /20 μg EE combination pills once daily for 21 days followed by placebo once
      daily for 7 days during Cycle 1 (the Run-In phase). Following completion of Cycle 1,
      participants were randomly assigned to receive either DR-1021 or Mircette during Cycle 2.
      All participants who completed Cycle 2 were to receive Kariva during Cycle 3; however,
      participants were only followed for the first 21 days of this 28-day regimen, after which
      they were considered study completers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Serum Estradiol Levels by Cycle Day</measure>
    <time_frame>Cycle 2, Day 2 (Baseline), and Days 4, 6, 19-20, 23, 24, 25, 27, 28, Cycle 3, Days 2, 4 and 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Levels of estradiol were measured throughout the study from blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Follicle Stimulating Hormone (FSH) Levels by Cycle Day</measure>
    <time_frame>Cycle 2, Day 2 (Baseline), and Days 4, 6, 19-20, 23, 24, 25, 27, 28, Cycle 3, Days 2, 4 and 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Levels of follicle stimulating hormone were measured throughout the study from blood samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Inhibin-B Levels by Cycle Day</measure>
    <time_frame>Cycle 2, Day 2 (Baseline), and Days 4, 6, 19-20, 23, 24, 25, 27, 28, Cycle 3, Days 2, 4 and 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Levels of inhibin-B were measured throughout the study from blood samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Follicles Greater Than 5 mm in Diameter</measure>
    <time_frame>Cycle 1, Days 11, 19-20, 23, 25, 27, Cycle 2, Days 4, 11, 19-20, 23, 25, 27, Cycle 3, Day 4.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ovarian follicles were measured by trans-vaginal ultrasound. The size of the 3 largest follicles was documented for each participant, and the percentage of follicles greater than 5 mm in diameter was calculated based on the total number follicles present (indicated by n for each time point).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Cycle 2 Days 1 - 20 to Cycle 2 Days 21 - 28 in Maximum Follicle Size</measure>
    <time_frame>Cycle 2, Days 1-20 and Cycle 2, Days 21-28</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the size of the largest documented follicle during combination therapy (Days 1 to 21) and during monotherapy/placebo (Days 21-28) measured by trans-vaginal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Bleeding or Spotting During Unscheduled and Scheduled Study Periods</measure>
    <time_frame>Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21</time_frame>
    <safety_issue>No</safety_issue>
    <description>The total number of days of unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding or spotting was derived from participant diaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Bleeding or Spotting During Unscheduled and Scheduled Study Periods</measure>
    <time_frame>Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants with unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding or spotting was derived from participant diaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Bleeding During Unscheduled and Scheduled Study Periods</measure>
    <time_frame>Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21</time_frame>
    <safety_issue>No</safety_issue>
    <description>The total number of days of unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding (not including spotting) was derived from participant diaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Bleeding During Unscheduled and Scheduled Study Periods</measure>
    <time_frame>Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants with unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding (not including spotting) was derived from participant diaries.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>DR-1021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mircette</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DR-1021</intervention_name>
    <description>Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus seven 10 μg EE tablets.</description>
    <arm_group_label>DR-1021</arm_group_label>
    <other_name>desogestrel/ethinyl estradiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mircette®</intervention_name>
    <description>Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.</description>
    <arm_group_label>Mircette</arm_group_label>
    <other_name>desogestrel/ethinyl estradiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kariva®</intervention_name>
    <description>Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.</description>
    <arm_group_label>DR-1021</arm_group_label>
    <arm_group_label>Mircette</arm_group_label>
    <other_name>desogestrel/ethinyl estradiol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal

          -  Weight &lt;200 lbs

          -  Currently taking or willing to be treated with an oral contraceptive with a standard
             21/7 regimen for one cycle prior to starting Study Cycle 1

          -  Others as dictated by protocol

        Exclusion Criteria:

          -  Any contraindication to the use of oral contraceptives

          -  Breast feeding

          -  Smoking &gt; 10 cigarettes per day

          -  Use of drugs that require simultaneous use of contraceptives (e.g., isotretinoin
             [Accutane])

          -  Others as dictated by protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duramed Protocol Chair</last_name>
    <role>Study Chair</role>
    <affiliation>Duramed Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>October 12, 2007</firstreceived_date>
  <firstreceived_results_date>May 8, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Desogestrel</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Female volunteers, aged 18-35 years old who were current users of a standard 21/7 oral contraceptive regimen (21 days of combination progestin/estrogen followed by 7 days placebo) were enrolled at 4 investigative sites in the United States.</recruitment_details>
      <pre_assignment_details>67 women were screened for participation in this study; 61 were enrolled and took at least 1 dose of their current regimen of oral contraceptive in Cycle 1 (the Run-in Cycle). Of the 61 enrolled, 3 participants discontinued the study prior to completing the Run-in Cycle and were therefore not randomly assigned to study drug in Cycle 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DR-1021</title>
          <description>After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
        </group>
        <group group_id="P2">
          <title>Mircette</title>
          <description>After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29">Randomized to study treatment in Cycle 2</participants>
                <participants group_id="P2" count="29">Randomized to study treatment in Cycle 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26">Completed 21 days of Cycle 3</participants>
                <participants group_id="P2" count="28">Completed 21 days of Cycle 3</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent-to-treat (ITT) cohort consisted of all randomized participants who took at least one dose of randomized study medication and had at least one post-baseline efficacy measurement for at least one of the primary efficacy endpoints (FSH, inhibin-B, or estradiol).</population>
      <group_list>
        <group group_id="B1">
          <title>DR-1021</title>
          <description>After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
        </group>
        <group group_id="B2">
          <title>Mircette</title>
          <description>After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="56"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="27.3" spread="4.68"/>
                <measurement group_id="B2" value="28.0" spread="4.38"/>
                <measurement group_id="B3" value="27.7" spread="4.51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="56"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>African-American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Caucasian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Hispanic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="56"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Estradiol Levels by Cycle Day</title>
        <description>Levels of estradiol were measured throughout the study from blood samples.</description>
        <time_frame>Cycle 2, Day 2 (Baseline), and Days 4, 6, 19-20, 23, 24, 25, 27, 28, Cycle 3, Days 2, 4 and 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population with available data at each time point (as indicated by n).</population>
        <group_list>
          <group group_id="O1">
            <title>DR-1021</title>
            <description>After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
          <group group_id="O2">
            <title>Mircette</title>
            <description>After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Serum Estradiol Levels by Cycle Day</title>
            <description>Levels of estradiol were measured throughout the study from blood samples.</description>
            <units>pg/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Cycle 2 - Day 2 (n=28, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47.00" lower_limit="15.0" upper_limit="361.0"/>
                  <measurement group_id="O2" value="51.50" lower_limit="6.0" upper_limit="322.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 4 (n=28, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="62.50" lower_limit="1.0" upper_limit="613.0"/>
                  <measurement group_id="O2" value="34.50" lower_limit="1.0" upper_limit="423.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 6 (n=27, 27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.00" lower_limit="1.0" upper_limit="579.0"/>
                  <measurement group_id="O2" value="29.00" lower_limit="1.0" upper_limit="274.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Days 19-20 (n=26, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19.00" lower_limit="1.0" upper_limit="152.0"/>
                  <measurement group_id="O2" value="20.50" lower_limit="1.0" upper_limit="327.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 23 (n=27, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24.00" lower_limit="1.0" upper_limit="204.0"/>
                  <measurement group_id="O2" value="19.00" lower_limit="1.0" upper_limit="159.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 24 (n=25, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.00" lower_limit="1.0" upper_limit="289.0"/>
                  <measurement group_id="O2" value="26.50" lower_limit="1.0" upper_limit="169.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 25 (n=27, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24.00" lower_limit="1.0" upper_limit="169.0"/>
                  <measurement group_id="O2" value="26.00" lower_limit="1.0" upper_limit="225.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 27 (n=25, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.00" lower_limit="1.0" upper_limit="233.0"/>
                  <measurement group_id="O2" value="20.00" lower_limit="1.0" upper_limit="213.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 28 (n=26, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36.00" lower_limit="1.0" upper_limit="284.0"/>
                  <measurement group_id="O2" value="27.50" lower_limit="1.0" upper_limit="332.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 3 - Day 2 (n=27, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34.00" lower_limit="1.0" upper_limit="425.0"/>
                  <measurement group_id="O2" value="43.00" lower_limit="3.0" upper_limit="217.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 3 - Day 4 (n=27, 27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66.00" lower_limit="1.0" upper_limit="440.0"/>
                  <measurement group_id="O2" value="27.00" lower_limit="1.0" upper_limit="295.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 3 - Day 6 (n=24, 26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28.50" lower_limit="1.0" upper_limit="277.0"/>
                  <measurement group_id="O2" value="32.00" lower_limit="3.0" upper_limit="197.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 2 time point. p-values &lt; 0.05 were considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.6346</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 4 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.2757</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 6 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.1321</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Days 19-20 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.5543</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 23 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.3940</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 24 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.7891</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 25 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.4829</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 27 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.4526</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 28 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.2485</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 3 - Day 2 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.6252</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 3 - Day 4 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.4003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 3 - Day 6 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.8841</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Follicles Greater Than 5 mm in Diameter</title>
        <description>Ovarian follicles were measured by trans-vaginal ultrasound. The size of the 3 largest follicles was documented for each participant, and the percentage of follicles greater than 5 mm in diameter was calculated based on the total number follicles present (indicated by n for each time point).</description>
        <time_frame>Cycle 1, Days 11, 19-20, 23, 25, 27, Cycle 2, Days 4, 11, 19-20, 23, 25, 27, Cycle 3, Day 4.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>DR-1021</title>
            <description>After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
          <group group_id="O2">
            <title>Mircette</title>
            <description>After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Follicles Greater Than 5 mm in Diameter</title>
            <description>Ovarian follicles were measured by trans-vaginal ultrasound. The size of the 3 largest follicles was documented for each participant, and the percentage of follicles greater than 5 mm in diameter was calculated based on the total number follicles present (indicated by n for each time point).</description>
            <units>percentage of follicles</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Cycle 1 - Day 11 (n=63, 48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.2"/>
                  <measurement group_id="O2" value="29.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 1 - Day 19-20 (n= 47, 94)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.8"/>
                  <measurement group_id="O2" value="27.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 1 - Day 23 (n= 30, 76)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50.0"/>
                  <measurement group_id="O2" value="26.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 1 - Day 25 (n= 85, 106)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32.9"/>
                  <measurement group_id="O2" value="31.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 1 - Day 27 (n=135, 145)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.6"/>
                  <measurement group_id="O2" value="35.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 4 (n=154, 156)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35.1"/>
                  <measurement group_id="O2" value="31.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 11 (n=76, 54)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.6"/>
                  <measurement group_id="O2" value="31.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Days 19-20 (n=143, 148)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17.5"/>
                  <measurement group_id="O2" value="18.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 23 (n=91, 62)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24.2"/>
                  <measurement group_id="O2" value="24.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 25 (n=69, 80)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.4"/>
                  <measurement group_id="O2" value="18.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 27 (n=94, 132)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23.4"/>
                  <measurement group_id="O2" value="20.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 3 - Day 4 (n=138, 117)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.4"/>
                  <measurement group_id="O2" value="27.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Follicle Stimulating Hormone (FSH) Levels by Cycle Day</title>
        <description>Levels of follicle stimulating hormone were measured throughout the study from blood samples.</description>
        <time_frame>Cycle 2, Day 2 (Baseline), and Days 4, 6, 19-20, 23, 24, 25, 27, 28, Cycle 3, Days 2, 4 and 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population with available data at each time point (as indicated by n).</population>
        <group_list>
          <group group_id="O1">
            <title>DR-1021</title>
            <description>After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
          <group group_id="O2">
            <title>Mircette</title>
            <description>After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Serum Follicle Stimulating Hormone (FSH) Levels by Cycle Day</title>
            <description>Levels of follicle stimulating hormone were measured throughout the study from blood samples.</description>
            <units>mIU/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Cycle 2 - Day 2 (n=28, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.00" lower_limit="2.3" upper_limit="9.7"/>
                  <measurement group_id="O2" value="4.00" lower_limit="1.2" upper_limit="7.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 4 (n=28, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.55" lower_limit="1.2" upper_limit="9.5"/>
                  <measurement group_id="O2" value="3.70" lower_limit="0.9" upper_limit="28.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 6 (n=28, 27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.70" lower_limit="0.4" upper_limit="8.5"/>
                  <measurement group_id="O2" value="3.50" lower_limit="0.2" upper_limit="14.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Days 19-20 (n=26, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.45" lower_limit="0.2" upper_limit="5.7"/>
                  <measurement group_id="O2" value="1.55" lower_limit="0.2" upper_limit="8.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 23 (n=27, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.70" lower_limit="0.2" upper_limit="6.3"/>
                  <measurement group_id="O2" value="2.35" lower_limit="0.2" upper_limit="6.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 24 (n=25, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.80" lower_limit="0.2" upper_limit="8.0"/>
                  <measurement group_id="O2" value="3.70" lower_limit="0.2" upper_limit="8.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 25 (n=27, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.90" lower_limit="0.2" upper_limit="8.0"/>
                  <measurement group_id="O2" value="3.90" lower_limit="0.2" upper_limit="11.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 27 (n=25, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.70" lower_limit="0.2" upper_limit="9.6"/>
                  <measurement group_id="O2" value="3.90" lower_limit="0.3" upper_limit="8.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 28 (n=26, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.05" lower_limit="0.2" upper_limit="11.0"/>
                  <measurement group_id="O2" value="4.70" lower_limit="0.4" upper_limit="25.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 3 - Day 2 (n=27, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.90" lower_limit="0.2" upper_limit="9.8"/>
                  <measurement group_id="O2" value="4.05" lower_limit="0.2" upper_limit="10.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 3 - Day 4 (n=27, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.70" lower_limit="0.2" upper_limit="8.0"/>
                  <measurement group_id="O2" value="3.60" lower_limit="0.2" upper_limit="8.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 3 - Day 6 (n=24, 26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.50" lower_limit="0.6" upper_limit="7.1"/>
                  <measurement group_id="O2" value="2.50" lower_limit="0.2" upper_limit="8.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 2 time point. p-values &lt; 0.05 were considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.8892</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 4 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.7678</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 6 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.5782</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Days 19-20 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.8083</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 23 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>1.0000</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 24 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.4122</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 25 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.6675</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 27 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.8445</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 28 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.3772</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 3 - Day 2 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.1918</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 3 - Day 4 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.6675</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 3 - Day 6 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.9226</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Inhibin-B Levels by Cycle Day</title>
        <description>Levels of inhibin-B were measured throughout the study from blood samples.</description>
        <time_frame>Cycle 2, Day 2 (Baseline), and Days 4, 6, 19-20, 23, 24, 25, 27, 28, Cycle 3, Days 2, 4 and 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population with available data at each time point (as indicated by n).</population>
        <group_list>
          <group group_id="O1">
            <title>DR-1021</title>
            <description>After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
          <group group_id="O2">
            <title>Mircette</title>
            <description>After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Serum Inhibin-B Levels by Cycle Day</title>
            <description>Levels of inhibin-B were measured throughout the study from blood samples.</description>
            <units>pg/mL</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Cycle 2 - Day 2 (n=28, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92.30" lower_limit="3.5" upper_limit="157.9"/>
                  <measurement group_id="O2" value="99.00" lower_limit="37.0" upper_limit="460.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 4 (n=28, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42.80" lower_limit="13.3" upper_limit="128.9"/>
                  <measurement group_id="O2" value="64.45" lower_limit="15.9" upper_limit="197.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 6 (n=28, 27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46.35" lower_limit="3.5" upper_limit="186.9"/>
                  <measurement group_id="O2" value="41.20" lower_limit="12.7" upper_limit="207.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Days 19-20 (n=26, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23.15" lower_limit="3.5" upper_limit="203.4"/>
                  <measurement group_id="O2" value="28.85" lower_limit="3.5" upper_limit="159.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 23 (n=27, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28.10" lower_limit="3.5" upper_limit="159.3"/>
                  <measurement group_id="O2" value="32.15" lower_limit="3.5" upper_limit="170.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 24 (n=25, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36.80" lower_limit="3.5" upper_limit="142.8"/>
                  <measurement group_id="O2" value="55.00" lower_limit="3.5" upper_limit="200.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 25 (n=27, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35.20" lower_limit="3.5" upper_limit="148.5"/>
                  <measurement group_id="O2" value="62.30" lower_limit="3.5" upper_limit="156.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 27 (n=25, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39.60" lower_limit="3.5" upper_limit="152.6"/>
                  <measurement group_id="O2" value="49.20" lower_limit="3.5" upper_limit="127.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 - Day 28 (n=26, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41.95" lower_limit="3.5" upper_limit="149.8"/>
                  <measurement group_id="O2" value="55.05" lower_limit="3.5" upper_limit="160.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 3 - Day 2 (n=27, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54.70" lower_limit="3.5" upper_limit="136.5"/>
                  <measurement group_id="O2" value="57.95" lower_limit="3.5" upper_limit="162.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 3 - Day 4 (n=27, 28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="51.10" lower_limit="3.5" upper_limit="122.1"/>
                  <measurement group_id="O2" value="52.25" lower_limit="3.5" upper_limit="183.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 3 - Day 6 (n=24, 26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36.15" lower_limit="3.5" upper_limit="211.7"/>
                  <measurement group_id="O2" value="29.55" lower_limit="3.5" upper_limit="141.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 2 time point. p-values &lt; 0.05 were considered statistically significant.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0979</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 4 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0629</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 6 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.8464</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Days 19-20 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.6316</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 23 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.3000</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 24 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0955</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 3 - Day 25 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.1523</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 2 - Day 27 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.2809</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 3 - Day 28 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.8829</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 3 - Day 2 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.9262</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 3 -Day 4 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.7811</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of treatment groups at Cycle 3 - Day 6 time point.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.3703</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Cycle 2 Days 1 - 20 to Cycle 2 Days 21 - 28 in Maximum Follicle Size</title>
        <description>The change in the size of the largest documented follicle during combination therapy (Days 1 to 21) and during monotherapy/placebo (Days 21-28) measured by trans-vaginal ultrasound.</description>
        <time_frame>Cycle 2, Days 1-20 and Cycle 2, Days 21-28</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat population with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>DR-1021</title>
            <description>After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
          <group group_id="O2">
            <title>Mircette</title>
            <description>After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Cycle 2 Days 1 - 20 to Cycle 2 Days 21 - 28 in Maximum Follicle Size</title>
            <description>The change in the size of the largest documented follicle during combination therapy (Days 1 to 21) and during monotherapy/placebo (Days 21-28) measured by trans-vaginal ultrasound.</description>
            <units>mm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-2.02" spread="6.076"/>
                  <measurement group_id="O2" value="-1.79" spread="3.081"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Bleeding or Spotting During Unscheduled and Scheduled Study Periods</title>
        <description>The total number of days of unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding or spotting was derived from participant diaries.</description>
        <time_frame>Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>DR-1021</title>
            <description>After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
          <group group_id="O2">
            <title>Mircette</title>
            <description>After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Days of Bleeding or Spotting During Unscheduled and Scheduled Study Periods</title>
            <description>The total number of days of unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding or spotting was derived from participant diaries.</description>
            <units>days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Cycle 2 – Unscheduled (Day 1-21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.19" spread="3.732"/>
                  <measurement group_id="O2" value="1.41" spread="1.551"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 – Scheduled (Day 22-28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.19" spread="2.167"/>
                  <measurement group_id="O2" value="3.67" spread="1.754"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 3 – Unscheduled (Day 1-21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.96" spread="2.808"/>
                  <measurement group_id="O2" value="1.64" spread="2.614"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Bleeding or Spotting During Unscheduled and Scheduled Study Periods</title>
        <description>The percentage of participants with unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding or spotting was derived from participant diaries.</description>
        <time_frame>Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>DR-1021</title>
            <description>After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
          <group group_id="O2">
            <title>Mircette</title>
            <description>After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Bleeding or Spotting During Unscheduled and Scheduled Study Periods</title>
            <description>The percentage of participants with unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding or spotting was derived from participant diaries.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Cycle 2 – Unscheduled (Day 1-21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48.1"/>
                  <measurement group_id="O2" value="59.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 – Scheduled (Day 22-28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77.8"/>
                  <measurement group_id="O2" value="92.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 3 – Unscheduled (Day 1-21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55.6"/>
                  <measurement group_id="O2" value="53.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Bleeding During Unscheduled and Scheduled Study Periods</title>
        <description>The total number of days of unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding (not including spotting) was derived from participant diaries.</description>
        <time_frame>Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>DR-1021</title>
            <description>After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
          <group group_id="O2">
            <title>Mircette</title>
            <description>After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Days of Bleeding During Unscheduled and Scheduled Study Periods</title>
            <description>The total number of days of unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding (not including spotting) was derived from participant diaries.</description>
            <units>days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Cycle 2 – Unscheduled (Day 1-21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.70" spread="2.127"/>
                  <measurement group_id="O2" value="0.52" spread="0.935"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 – Scheduled (Day 22-28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.30" spread="1.793"/>
                  <measurement group_id="O2" value="2.63" spread="1.843"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 3 – Unscheduled (Day 1-21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.70" spread="1.436"/>
                  <measurement group_id="O2" value="0.71" spread="1.607"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Bleeding During Unscheduled and Scheduled Study Periods</title>
        <description>The percentage of participants with unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding (not including spotting) was derived from participant diaries.</description>
        <time_frame>Cycle 2, Days 1-21, Cycle 2, Days 22-28 and Cycle 3, Days 1-21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>DR-1021</title>
            <description>After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
          <group group_id="O2">
            <title>Mircette</title>
            <description>After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Bleeding During Unscheduled and Scheduled Study Periods</title>
            <description>The percentage of participants with unscheduled (Day 1 to Day 21 of each cycle) and scheduled (ie,withdrawal [Day 22 to Day 28 of each cycle]) bleeding (not including spotting) was derived from participant diaries.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Cycle 2 – Unscheduled (Day 1-21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.5"/>
                  <measurement group_id="O2" value="33.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 2 – Scheduled (Day 22-28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77.8"/>
                  <measurement group_id="O2" value="77.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cycle 3 – Unscheduled (Day 1-21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.6"/>
                  <measurement group_id="O2" value="25.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the date of the first randomized dose through 14 days after the last randomized dose, up to 42 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DR-1021</title>
          <description>After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
        </group>
        <group group_id="E2">
          <title>Mircette</title>
          <description>After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor’s review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor’s designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Research</name_or_title>
      <organization>Teva Branded Pharmaceutical Products R&amp;D</organization>
      <phone>610-786-7047</phone>
      <email>clinicaltrialsdisclosure@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
